Movement Alert｜METIS TECHBIO-P Intraday Rise 5.32% in Regular Trading, Lilly LNP Collaboration Continues to Support Sentiment

Market Focus10-28

On October 28, METIS TECHBIO-P posted an Intraday Rise of 5.32% in Regular Trading, with the stock trading at HK$11.46 and turnover of HK$26.23 million.

The move aligns with continued market digestion of the company’s previously announced strategic collaboration with Eli Lilly on next-generation tissue-specific LNP delivery technology, which has kept attention on the commercialization value of its AI-driven delivery platform.

Under the disclosed terms, METIS TECHBIO-P is eligible to receive an upfront payment in the low double-digit millions of U.S. dollars, up to about US$1.1 billion in development, regulatory and commercial milestone payments, and potential single-digit tiered royalties. The collaboration uses its AiLNP platform to discover and optimize novel lipid nanoparticle architectures, and recent market commentary indicates the platform-validation significance of the deal remains a key support for the shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment